Contact this trialFirst, we need to learn more about you.
Small Molecule Drug
ARM210 for Ventricular Tachycardia
Recruiting0 awardsPhase 2
Rochester, Minnesota
This trial is testing a new drug, S48168 (ARM210), to see if it is safe and effective in treating Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1). This disease causes fatal changes in heart rhythms, leading to sudden death with exercise or excitement. The new drug is designed to repair the leaky channels that cause the disease. If it is effective, it would allow people with CPVT to live normal, active lives.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.